精准靶向激酶。
Targeting kinases with precision.
作者信息
Gardino Alexandra K, Evans Erica K, Kim Joseph L, Brooijmans Natasja, Hodous Brian L, Wolf Beni, Lengauer Christoph
机构信息
Blueprint Medicines, Cambridge, MA, USA.
Accent Therapeutics, Cambridge, MA, USA.
出版信息
Mol Cell Oncol. 2018 Apr 11;5(3):e1435183. doi: 10.1080/23723556.2018.1435183. eCollection 2018.
Abstract
Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in a variety of activation mechanisms. The challenge has been to match these insights with tailored drug discovery strategies to yield potent, highly selective drugs. With optimized drugs in hand, physicians could apply the principles of personalized medicine with an increasing number of options to treat patients with improved precision according to their tumor's molecular genotype.
摘要
癌症基因组学和机制研究表明，单一激酶内的异质性突变可导致多种激活机制。挑战在于将这些见解与量身定制的药物发现策略相匹配，以产生强效、高选择性的药物。有了优化后的药物，医生可以应用个性化医疗原则，根据患者肿瘤的分子基因型，有越来越多的选择来更精准地治疗患者。
相似文献
1
Targeting kinases with precision.
Mol Cell Oncol. 2018 Apr 11;5(3):e1435183. doi: 10.1080/23723556.2018.1435183. eCollection 2018.
2
A precision therapy against cancers driven by mutations.
Sci Transl Med. 2017 Nov 1;9(414). doi: 10.1126/scitranslmed.aao1690.
3
Successful treatment with avapritinib in patient with mucosal metastatic melanoma.
Ther Adv Med Oncol. 2020 Jul 31;12:1758835920946158. doi: 10.1177/1758835920946158. eCollection 2020.
4
Novel approaches to treating advanced systemic mastocytosis.
Clin Pharmacol. 2019 Jul 10;11:77-92. doi: 10.2147/CPAA.S206615. eCollection 2019.
5
Precision medicine review: rare driver mutations and their biophysical classification.
Biophys Rev. 2019 Feb;11(1):5-19. doi: 10.1007/s12551-018-0496-2. Epub 2019 Jan 4.
6
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Clin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1.
7
Rapid Responses to Avapritinib (BLU-285) in Mastocytosis.
Cancer Discov. 2018 Feb;8(2):133. doi: 10.1158/2159-8290.CD-NB2017-177. Epub 2017 Dec 12.
8
Novel Approaches for Systemic Mastocytosis.
Curr Opin Hematol. 2019 Mar;26(2):112-118. doi: 10.1097/MOH.0000000000000486.
9
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Curr Hematol Malig Rep. 2018 Oct;13(5):407-416. doi: 10.1007/s11899-018-0469-3.
10
Precision medicine in gastrointestinal stromal tumors.
Discov Med. 2019 Nov-Dec;28(155):267-276.
引用本文的文献
1
Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation.
Leuk Res Rep. 2023 Dec 30;21:100409. doi: 10.1016/j.lrr.2023.100409. eCollection 2024.
2
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA.
Nat Commun. 2024 Jan 2;15(1):63. doi: 10.1038/s41467-023-44376-8.
3
Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision.
Cancers (Basel). 2023 Feb 27;15(5):1498. doi: 10.3390/cancers15051498.
4
Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes.
Cell Mol Bioeng. 2022 Nov 15;15(5):521-533. doi: 10.1007/s12195-022-00748-6. eCollection 2022 Oct.
5
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
RSC Med Chem. 2022 Aug 26;13(11):1300-1321. doi: 10.1039/d2md00206j. eCollection 2022 Nov 16.
6
Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging).
Curr Drug Deliv. 2024;21(1):80-90. doi: 10.2174/1567201820666221122120657.
7
Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications.
Cancers (Basel). 2022 Oct 29;14(21):5330. doi: 10.3390/cancers14215330.
8
Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.
J Chem Theory Comput. 2022 Oct 11;18(10):6251-6258. doi: 10.1021/acs.jctc.2c00526. Epub 2022 Sep 27.
9
KinCon: Cell-based recording of full-length kinase conformations.
IUBMB Life. 2020 Jun;72(6):1168-1174. doi: 10.1002/iub.2241. Epub 2020 Feb 6.
本文引用的文献
1
A precision therapy against cancers driven by mutations.
Sci Transl Med. 2017 Nov 1;9(414). doi: 10.1126/scitranslmed.aao1690.
2
AACR Project GENIE: Powering Precision Medicine through an International Consortium.
Cancer Discov. 2017 Aug;7(8):818-831. doi: 10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1.
3
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Clin Cancer Res. 2012 Aug 15;18(16):4458-64. doi: 10.1158/1078-0432.CCR-11-3025. Epub 2012 Jun 20.
4
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Cancer Discov. 2012 May;2(5):401-4. doi: 10.1158/2159-8290.CD-12-0095.
5
The GIST paradigm: lessons for other kinase-driven cancers.
J Pathol. 2011 Jan;223(2):251-61. doi: 10.1002/path.2798. Epub 2010 Oct 26.
6
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21.
7
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
Blood. 2006 Oct 1;108(7):2366-72. doi: 10.1182/blood-2006-04-015545. Epub 2006 Jun 1.
8
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461.
Zotero 插件